The Next MedTech Frontier: Automated Insulin Delivery Adapts to Type 2 Diabetes

MANCHESTER, N.H. — October 16, 2026 — For over a decade, the narrative surrounding diabetes technology has been largely bifurcated. The most sophisticated innovations—specifically, automated insulin delivery (AID) systems—were developed for and marketed almost exclusively to individuals with type 1 diabetes. Meanwhile, the vast majority of insulin users, those living with type 2 diabetes, were left to navigate a labyrinth of manual injections, complex dosage calculations, and the constant cognitive burden of disease management.

Today, that paradigm shifts significantly. Sequel Med Tech announced that its twiist Automated Insulin Delivery System has received clearance from the U.S. Food and Drug Administration (FDA) for adults aged 18 and older with insulin-treated type 2 diabetes. Following its initial rollout for type 1 diabetes earlier this year, this expansion opens the door to an estimated 5.5 million Americans who rely on insulin to manage their type 2 diabetes.

At the intersection of biotechnology, consumer hardware, and modern pharmacology, this clearance represents more than just a new product launch. It signals a fundamental realignment in how the medical technology sector views the type 2 diabetes market, moving away from a "one-size-fits-all" manual approach toward highly personalized, algorithm-driven care.

Bridging the Diabetes Tech Divide

Historically, the barrier to bringing automated pumps to the type 2 community wasn't just physiological; it was rooted in usability and market assumptions. Traditional insulin pumps often required rigorous training, meticulous carbohydrate counting, and a steep learning curve—prerequisites that alienated many type 2 patients and their primary care providers.

The twiist system was designed to dismantle these exact barriers. Powered by the twiist Loop algorithm—derived from the community-driven Tidepool Loop—the device continuously adjusts basal insulin delivery based on real-time glucose data. It is underpinned by proprietary iiSure Technology, which directly measures the volume of insulin delivered with every microdose and detects blockages up to nine times faster than legacy systems.

Data from a 13-week, 307-patient pivotal trial, recently published in Diabetes Care, underscores the efficacy of this simplified approach. Trial participants spent a median of 95% of the study in automated delivery mode, despite only 11% having prior carbohydrate-counting experience and a mere 19% having ever used an AID system.

The clinical outcomes were striking. Participants saw an average HbA1c reduction of 0.7%, with those starting at a baseline of 9.0% or higher experiencing a massive 2.1% drop. Time in the target glucose range (70 to 180 mg/dL) increased from 57% to 73%, granting users an average of 3.8 additional hours per day in a healthy range.

"What we’re seeing with twiist represents a real inflection point for adults with type 2 diabetes who rely on insulin," said Dr. Osama Hamdy of the Joslin Diabetes Center, an investigator in the trial. "Many people intensify therapy, adjust doses, and follow complex regimens but still struggle to reach glucose targets. This trial shows how twiist can change that trajectory... delivering the kind of burden-free improvement this community has long needed."

The Race to Automate a 5.5 Million Patient Market

The commercial implications of Sequel's FDA clearance are vast. The medtech industry is currently locked in a race to capture the 5.5 million Americans with type 2 diabetes who require insulin—a market exponentially larger than the type 1 population.

Sequel enters a competitive landscape that includes heavyweights like Insulet, which secured type 2 clearance for its Omnipod 5 system, and Tandem Diabetes Care's t:slim X2. However, Sequel is positioning twiist to compete on specific lifestyle and accessibility vectors. The device features a robust 300-unit insulin capacity and requires a cassette change only once every three days. Furthermore, it integrates seamlessly with continuous glucose monitors (CGMs) already popular in the type 2 community, specifically Abbott's FreeStyle Libre 3 Plus and Senseonics' newly cleared Eversense 365.

Perhaps the most disruptive element of Sequel's strategy is its distribution model. Historically, insulin pumps have been bogged down in the cumbersome Durable Medical Equipment (DME) insurance pathway, which is notorious for extensive paperwork and delays. Sequel is heavily pushing a "low friction pharmacy start," aiming to process the twiist system through standard pharmacy benefits. This strategy mirrors the ease of picking up a monthly prescription, drastically reducing the friction of adoption for both patients and prescribing physicians.

"For many adults living with type 2 diabetes, insulin therapy can feel like one more thing to manage in an already busy life," noted Sequel CEO and Co-Founder Alan Lotvin, MD. "At Sequel, we believe technology should meet people where they are, not the other way around."

Hardware Meets the GLP-1 Era

You cannot analyze the modern landscape of metabolic health without addressing the pharmaceutical juggernauts of our time: GLP-1 receptor agonists and SGLT-2 inhibitors. A critical question for medtech developers has been how hardware solutions fit into a world increasingly dominated by these blockbuster drugs.

The twiist pivotal trial provided a definitive answer: they work synergistically. The study population reflected the reality of contemporary type 2 diabetes care, with 56% of participants actively using a GLP-1 receptor agonist and 37% on an SGLT-2 inhibitor.

Rather than rendering the pump obsolete, the combination proved highly effective. Participants achieved significant glycemic improvements while continuing their concurrent drug therapies. Notably, patients who transitioned from traditional basal-bolus injection regimens to the twiist system required an average of 19.3 fewer units of insulin per day. This reduction is clinically significant, as lower insulin doses can help mitigate the weight gain traditionally associated with intensive insulin therapy, perfectly complementing the weight-loss benefits of GLP-1 medications.

This synergy aligns flawlessly with the evolving clinical consensus. The 2026 American Diabetes Association (ADA) Standards of Care recently updated their guidelines to designate automated insulin delivery as the preferred insulin delivery method over multiple daily injections for adults with type 2 diabetes, notably removing previous prerequisites regarding C-peptide levels or autoantibodies.

Redefining Daily Disease Management

Beyond the clinical endpoints and market share battles lies the tangible impact on human lifestyle. The cognitive load of insulin-dependent diabetes is staggering. It requires a patient to act as a human pancreas, constantly calculating the variables of food intake, stress, physical activity, and medication.

The promise of systems like twiist is the outsourcing of this cognitive burden to an algorithm. In the pivotal trial, patient-reported outcomes highlighted significant improvements in both treatment satisfaction and sleep quality. Furthermore, the system achieved these results without a single reported event of severe hypoglycemia, historically one of the most terrifying risks associated with insulin therapy.

As we look at the broader trends shaping healthcare, the integration of consumer-friendly tech with clinical-grade medical devices is accelerating. With twiist acting as the first FDA-approved AID system that can be directly controlled via an Apple Watch, the line between a medical device and a lifestyle wearable continues to blur. For the millions of adults navigating the complexities of type 2 diabetes, this convergence of hardware, software, and pharmacology doesn't just promise better blood sugar numbers—it offers the return of their time and mental energy.